Nanexa AB (FRA:40M) Cyclically Adjusted Revenue per Share: €0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:40M Nanexa AB FRA:40M
53 GF Score
Price €0.32
GF Value €0.18
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nanexa AB Cyclically Adjusted Revenue per Share?

Nanexa AB FRA:40M +0.16% 53 Cyclically Adjusted Revenue per Share is €0.01 as of Mar. 2026. GuruFocus rates FRA:40M with a GF Score™ of 53/100 and a GF Value™ of €0.18 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nanexa AB's adjusted revenue per share for the three months ended in Mar. 2026 was €0.001. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.01 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Nanexa AB's average Cyclically Adjusted Revenue Growth Rate was 7.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-18), Nanexa AB's current stock price is €0.319. Nanexa AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.01. Nanexa AB's Cyclically Adjusted PS Ratio of today is 31.90.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Nanexa AB was 30.04. The lowest was 5.87. And the median was 15.21.


Nanexa AB  (FRA:40M) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nanexa AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.319/0.01
=31.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Nanexa AB was 30.04. The lowest was 5.87. And the median was 15.21.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nanexa AB Cyclically Adjusted Revenue per Share Related Terms


Nanexa AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Nanexa AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanexa AB Cyclically Adjusted Revenue per Share Chart

Nanexa AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.01 0.01

Nanexa AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

FRA:40M vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanexa AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nanexa AB's Cyclically Adjusted PS Ratio falls into.


FRA:40M
53GF Score
Nanexa AB FRA:40M
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanexa AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nanexa AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.001/133.5600*133.5600
=0.001

Current CPI (Mar. 2026) = 133.5600.

Nanexa AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.003 101.019 0.004
201609 0.001 101.138 0.001
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.000 102.752 0.000
201709 0.001 103.279 0.001
201712 0.000 103.793 0.000
201803 0.001 103.962 0.001
201806 0.000 104.875 0.000
201809 0.001 105.679 0.001
201812 0.001 105.912 0.001
201903 0.001 105.886 0.001
201906 0.004 106.742 0.005
201909 0.001 107.214 0.001
201912 0.004 107.766 0.005
202003 0.006 106.563 0.008
202006 0.000 107.498 0.000
202009 0.002 107.635 0.002
202012 0.002 108.296 0.002
202103 0.002 108.360 0.002
202106 0.001 108.928 0.001
202109 0.002 110.338 0.002
202112 0.001 112.486 0.001
202203 0.001 114.825 0.001
202206 0.000 118.384 0.000
202209 0.003 122.296 0.003
202212 0.001 126.365 0.001
202303 0.012 127.042 0.013
202306 0.010 129.407 0.010
202309 0.009 130.224 0.009
202312 0.006 131.912 0.006
202403 0.005 132.205 0.005
202406 0.004 132.716 0.004
202409 0.004 132.304 0.004
202412 0.003 132.987 0.003
202503 0.002 132.825 0.002
202506 0.001 133.699 0.001
202509 0.000 133.480 0.000
202512 0.017 133.390 0.017
202603 0.001 133.560 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.01 mean?
Nanexa AB (FRA:40M) has a Cyclically Adjusted Revenue per Share of €0.01 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nanexa AB and its competitors.
Is Nanexa AB's Cyclically Adjusted Revenue per Share too high?
Nanexa AB's current Cyclically Adjusted Revenue per Share is €0.01. Overall, Nanexa AB has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Nanexa AB's Cyclically Adjusted Revenue per Share of €0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nanexa AB and its competitors. Nanexa AB's current Cyclically Adjusted Revenue per Share is €0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (FRA:40M) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.18, compared to a current price of €0.32 — trading 77.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.01. Nanexa AB's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Nanexa AB (FRA:40M), the current Cyclically Adjusted Revenue per Share is €0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanexa AB (FRA:40M) Overvalued in 2026?

Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued. The current stock price of €0.32 is trading 77.2% above its estimated GF Value™ of €0.18. GuruFocus considers Nanexa AB to be Significantly Overvalued.

Key valuation signals for FRA:40M:

  • Cyclically Adjusted Revenue per Share: €0.01
  • GF Value™: €0.18 vs. price of €0.32 (77.2% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanexa AB Business Description

Other Exchanges NANEXA:Sweden
Address Virdings Alle 32B, Uppsala, SWE, 75450
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
53GF Score

Get the complete analysis for FRA:40M

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price
€0.18
GF Value